Reassessing bioavailability of silymarin

Alternative Medicine Review

Volumn 16, Issue 3, 2011, Pages 239-249

  Javed, Shamama ^a   Kohli, Kanchan ^a   Ali, Mushir ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Absorption; Bioavailability; Flavonoid; Flavonolignan; Liposomes; Milk thistle; Pharmacokinetics; Phytosomes; Silybin; Silybum; Silymarin; Solubility

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA CYCLODEXTRIN; DRUG METABOLITE; LECTIN RECEPTOR; LIPOSOME; MACROGOL; MICROSPHERE; NANOCARRIER; PRODRUG; SILIBININ; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILICRISTIN; SILIDIANIN; SILIPHOS; SILIREX; SILYMARIN; TAXIFOLIN; UNCLASSIFIED DRUG; YIGANLING; PLANT EXTRACT; PROTECTIVE AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TRANSFORMATION; GLYCOSYLATION; HUMAN; LIVER TOXICITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; RAMAN SPECTROMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SILYBUM MARIANUM; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE PREPARATION; TABLET FORMULATION; TISSUE DISTRIBUTION; BIOAVAILABILITY; PHYTOTHERAPY;

BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; PHYTOTHERAPY; PLANT EXTRACTS; PROTECTIVE AGENTS; SILYMARIN;

EID: 84856401398     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006;124:491-504. (Pubitemid 46157708)
2. Kren V, Walterova D. Silybin and silymarin - new effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005;149:29-41.
3. Koksal E, Gulcin I, Beyza S, et al. In vitro antioxidant activity of silymarin. J Enzyme Inhib Med Chem 2009;24:395-405.
4. Fraschini F, Demartini G, Esposti D. Pharmacology of silymarin. Clin Drug Investig 2002;22:51-65. (Pubitemid 34151333)
5. Sailer R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-2063. (Pubitemid 33135182)
6. Singh RP, Aggarwal R. Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 2004;4:1-11. (Pubitemid 38332560)
7. Yang SH, Lin JK, Chen WS, Chiu JH. Antiangiogenic effect of silymarin on colon cancer LoVo cell line. J Surg Res 2003;113:133-138.
8. Lirussi F, Beccarello A, Zanette G, et al. Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes Nutr Metab 2002;15:222-231. (Pubitemid 35189806)
9. Rao PR, Viswanath RK. Cardioprotective activity of silymarin in ischemia-reperfusion-induced myocardial infarction in albino rats. Exp Clin Cardio! 2007;12:179-187.
10. Radko L, Cybulski W. Application of silymarin in human and animal medicine. J Preclin Clin Res 2007;1:22-26.
11. Dixit N, Baboota S, Kohli K, et al. Silymarin: a review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol 2008;39:172-179. (Pubitemid 350005989)
12. Woo JS, Kim TS, Park JH, Chi SC. Formulation and biopharmaceutical evaluation of silymarin using SMEDDS. Arch Pharm Res 2007;30:82-89.
13. Wu JW, Lin LC, Tsai TH. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 2009;121:185-193.
14. Wu JW, Lin LC, Hung SC, et al. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharm Biomed Anal 2007;45:635-641.
15. Zhao J, Aggarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 1999;20:2101-2108. (Pubitemid 29535311)
16. Jancova P, Anzenbacherova E, Papouskova B, et al. Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos 2007;35:2035-2039. (Pubitemid 350005192)
17. Wu JW, Lin LC, Hung SC, et al. Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. Drug Metab Dispos 2008;36:589-596.
18. Wen Z, Dumas TE, Schrieber SJ, et al. Pharmacokinetics and metabolic profiles of free, conjugated and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 2008;36:65-72.
19. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 2005;10:193-203. (Pubitemid 41384033)
20. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea and grape seed extracts. Altern Med Rev 2009;14:226-246.
21. Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on Idb 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990;15:333-338.
22. Morazzoni P, Magistretti MJ, Giachetti C, Zanolo G. Comparative bioavailability of Silipide, a new flavanolignan complex, in rats. Eur J Drug Metab Pharmacokinet 1992;17:39-44.
23. Morazzoni P, Montalbetti A, Malandrino S, Pifferi G. Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet 1993;18:289-297. (Pubitemid 24009653)
24. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung 1992;42:964-968.
25. Skottová N, SVagera Z, Vecera R, et al. Pharmacokinetic study of iodine-labeled silibinins in rat. Pharmacol Res 2001;44:247-253.
26. Yanyu X, Yunmei S, Zhipeng C, Quieng P. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm 2006;307:77-82. (Pubitemid 41773254)
27. Filburn CR, Kettenacker R, Griffin DW. Bioavailability of a silybin-phosphatidylcholine complex in dogs. J Vet Pharmacol Ther 2007;30:132-138. (Pubitemid 46365043)
28. Verschoyle RD, Greaves P, Patel K, et al. Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels. Eur J Cancer 2008;44:898-906.
29. Fang JY. Nano- or submicron-sized liposomes as carriers for drug delivery. Chang Gung Med J 2006;29:358-362.
30. Maheshwari H, Aggarwal R, Patil C, Katare OP. Preparation and pharmacological evaluation of silibinin liposomes. Arzneimittelforschung 2003;53:420-427. (Pubitemid 36776132)
31. Xiao YY, Song YM, Chen ZP, Ping QN. Preparation of silymarin proliposomes and its pharmacokinetics in rats. Yao Xue Xue Bao 2005;40:758-763. [Article in Chinese]
32. Yan-yu X, Yun-mei S, Zhi-peng C, Qi-neng P. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. Int J Pharm 2006;319:162-168. (Pubitemid 44051803)
33. El-Samaligy MS, Afifi NN, Mahmoud EA. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. Int J Pharm 2006;308:140-148. (Pubitemid 43097245)
34. El-Samaligy MS, Afifi NN, Mahmoud EA. Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. Int J Pharm 2006;319:121-129. (Pubitemid 44051811)
35. Dube D, Khatri K, Goyal AK, et al. Preparation and evaluation of galactosylated vesicular carrier for hepatic targeting of silibinin. Drug Dev Ind Pharm 2010;36:547-555.
36. Chaubal MV. Application of drug delivery technologies in lead candidate selection and optimization. Drug Discov Today 2004;9:603-609. (Pubitemid 38900510)
37. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 2007;123:78-99. (Pubitemid 47566400)
38. Arcari M, Brambilla A, Brandt A, et al. A new inclusion complex of silibinin and beta-cyclodextrins: in vitro dissolution kinetics and in vivo absorption in comparison with traditional formulations. Boll Chim Farm 1992;131:205-209. [Article in Italian]
39. Voinovich D, Perissutti B, Grassi M, et al. Solid state mechanochemical activation of Silybum marianum dry extract with betacyclodextrins: characterization and bioavailability of the coground systems. J Pharm Sci 2009;98:4119-4129.
40. Sethia S, Squillante E. Solid dispersions: revival with greater possibilities and applications in oral drug delivery. Crit Rev Ther Drug Carrier Syst 2003;20:215-247. (Pubitemid 37237280)
41. Li FQ, Hu JH, Wang H, et al. Relativities between lattice changes and the function of dissolution improvement of poorly soluble drug silymarin based upon PEG 6,000 solid dispersion system. Yao Xue Xue Bao 2002;37:294-298. [Article in Chinese]
42. Li FQ, Hu JH. Improvement of the dissolution rate of silymarin by means of solid dispersions. Chem Pharm Bull (Tokyo) 2004;52:972-973.
43. Zhang P, Ye H, Min T, Zhang C. Water soluble poly (ethylene glycol) prodrug of silybin: design, synthesis, and characterization. J Appl Polym Sci Symp 2008;107:3230-3235. (Pubitemid 351238758)
44. Qiu MF, Jia W, Li SS, et al. A new silymarin preparation based on solid dispersion technique. Adv Ther 2005;22:595-600.
45. Nakhat PD, Naidu RA, Babla IB, et al. Design and evaluation of silymarin-HP-beta-CD solid dispersion tablets. Indian J Pharm Sci 2007;69:287-289.
46. Sun N, Wei X, Wu B, Chen J, Lu Y, Wu W. Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. Powder Technol 2008;182:72-80. (Pubitemid 351173199)
47. Sun N, Zhang X, Lu Y, Wu W. In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing silybum marianum extract prepared by fluid-bed coating. Planta Med 2008;74:126-132. (Pubitemid 351340615)
48. Kren V, Kubisch J, Sedmera P, et al. Glycosylation of silybin. J Chem Soc 1997;1:2467-2474. (Pubitemid 127785716)
49. Mira L, Silva M, Manso CF. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol 1994;48:753-759. (Pubitemid 24283845)
50. Carducci R, Armellino MF, Volpe C, et al. Silibinin and acute poisoning with Amanita phalloides. Minerva Anestesiol 1996;62:187-193. [Article in Italian]
51. Pifferi G, Pace R, Conti M. Synthesis and antihepatotoxic activity of silybin 11-O-phosphate. Farmaco 1994;49:75-76. (Pubitemid 24099105)
52. Kosina P, Kren V, Gebhardt R, et al. Antioxidant properties of silybin glycosides. Phytother Res 2002;16:S33-S39. (Pubitemid 34297477)
53. Kosina P, Maurel P, Ulrichová J, Dvorák Z. Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2005;19:149-153. (Pubitemid 40967281)
54. Gazak R, Svobodová A, Psotová J, et al. Oxidised derivatives of silybin and their antiradical and antioxidant activity. Bioorg Med Chem 2004;12:5677-5687. (Pubitemid 39304066)
55. Dzubak P, Hajduch M, Gazak R, et al. New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. Bioorg Med Chem 2006;14:3793-3810.
56. Zhang HL, Bai TC, Yan GB, Hu J. Solubility of silybin in aqueous poly(vinylpyrrolidone) solution. Fluid Phase Equilib 2005;238:186-192. (Pubitemid 41681697)
57. Bai TC, Yan GB, Zhang HL, Hu J. Solubility of silybin in aqueous dextran solutions. J Chem Eng Data 2005;50:1596-1601. (Pubitemid 41381037)
58. Bai TC, Yan GB, Hu J, et al. Solubility of silybin in aqueous poly(ethylene glycol) solution. Int J Pharm 2006;308:100-106. (Pubitemid 43097240)
59. Bai TC, Zhu JJ, Hu J, et al. Solubility of silybin in aqueous hydrochloric acid solution. Fluid Phase Equilib 2007;254:204-210. (Pubitemid 46660375)
60. Garg R, Gupta GD. Preparation and evaluation of gastroretentive floating tablets of silymarin. Chem Pharm Bull (Tokyo) 2009;57:545-549.
61. Savio D, Harrasser PC, Basso G. Softgel capsule technology as an enhancer device for the absorption of natural principles in humans. A bioavailability cross-over randomised study on silybin. Arzneimittelforschung 1998;48:1104-1106. (Pubitemid 28535595)
62. Debbage P. Targeted drugs and nanomedicine: present and future. Curr Pharm Des 2009;15:153-172.
63. Di Pierro F, Callegari A, Carotenuto D, Tapia MM. Clinical efficacy, safety and tolerability of BIO-C (micronized Silymarin) as galactagogue. Acta Biomed 2008;79:205-210.
64. Capasso R, Aviello G, Capasso F, et al. Silymarin BIO-C, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. Phytomedicine 2009;16:839-844.
65. Zhang ZB, Shen ZG, Wang JX, et al. Micronization of silybin by the emulsion solvent diffusion method. Int J Pharm 2009;376:116-122.
66. Hung CF, Lin YK, Zhang LW, et al. Topical delivery of silymarin constituents via the skin route. Acta Pharmacol Sin 2010;31:118-126.
67. Lu C, Lu Y, Chen J, et al. Synchronized and sustained release of multiple components in silymarin from erodible glyceryl monostearate matrix system. Eur J Pharm Biopharm 2007;66:210-219. (Pubitemid 46654778)
68. Abrol S, Trehan A, Katare OP. Formulation, characterization, and in vitro evaluation of silymarin-loaded lipid microspheres. Drug Deliv 2004;11:185-191. (Pubitemid 38720415)
69. Abrol S, Trehan A, Katare OP. Comparative study of different silymarin formulations: formulation, characterisation and in vitro/in vivo evaluation. Curr Drug Deliv 2005;2:45-51. (Pubitemid 40590920)
70. http://www.pharmainfo.net/nanocarriers [Accessed: August 24, 2011]
71. El-Sherbiny IM, Abdel-Mogib M, Dawidar AM, et al. Biodegradable pH-responsive alginate-poly (lactic-co-glycolic acid) nano/micro hydrogel matrices for oral delivery of silymarin. Carbohydr Polym 2011;83:1345-1354.
72. Parveen R, Baboota S, Ali J, et al. Oil based nanocarrier for improved oral delivery of silymarin: in vitro and in vivo studies. Int J Pharm 2011;413:245-253.
73. He J, Feng JF, Zhang LL, et al. Freeze-drying of silymarin-loaded solid lipid nanoparticles (SM-SLN). Zhongguo Zhong Yao Za Zhi 2005;30:110-112. [Article in Chinese] (Pubitemid 44366796)
74. Jun H, Shixiang H, Weigen L, et al. Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J Biomed Nanotechnol 2007;3:195-202.
75. Xu XM, Li Q, Zhu Y, et al. Study on the preparation and bio-distribution of silybin lipid nanospheres. Zhongguo Zhong Yao Za Zhi 2005;30:1912-1914. (Pubitemid 44888647)
76. Gao HL, Pang ZQ, Fan L, et al. Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: in vitro and in vivo evaluations. Acta Pharmacol Sin 2010;31:237-243.
77. Stevens AJ, Martin SW, Brennan BS, et al. Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. Pharm Res 1995;12:1987-1996. (Pubitemid 26031787)
78. Zhang JQ, Liu J, LiXL, Jasti BR. Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv 2007;14:381-387. (Pubitemid 47265822)
79. Jia LJ, Zhang DR, Li ZY, et al. Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug Deliv 2009 Nov 26 [Epub ahead of print]
80. Porter CJ, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev 2008;60:673-691.
81. Yuan Q, Li XR, Wang HJ, et al. The absorption kinetics of silymarin microemulsion in rat intestine. Yao Xue Xue Bao 2004;39:631-634. [Article in Chinese] (Pubitemid 39656387)
82. Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm 2006;63:288-294. (Pubitemid 43776222)
83. Liu L, Pang X, Zhang W, Wang S. Formulation design and in vitro evaluation of silymarin loaded self micro emulsifying drug delivery systems. Asian J Pharm Sci 2007;2:150-160.
84. Wu YP, Huo MR, Zhou JP. Preparation of silymarin-loaded amphiphilic chitosan micelle and its in situ absorption in rat intestine. Yao Xue Xue Bao 2009;44:651-657. [Article in Chinese]
85. Li X, Huang Y, Chen X, et al. Self-assembly and characterization of Pluronic P105 micelles for liver-targeted delivery of silybin. J Drug Target 2009;17:739-750.